| Title | Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. |
| Publication Type | Journal Article |
| Year of Publication | 2019 |
| Authors | Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S |
| Journal | Leuk Lymphoma |
| Volume | 60 |
| Issue | 7 |
| Pagination | 1626-1631 |
| Date Published | 2019 07 |
| ISSN | 1029-2403 |
| Keywords | Drug Resistance, Neoplasm, Drug Therapy, Combination, Humans, Janus Kinase 1, Janus Kinase 2, Janus Kinase 3, Leukemia, Prolymphocytic, T-Cell, Male, Middle Aged, Mutation, Piperidines, Prognosis, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines, Pyrroles |
| DOI | 10.1080/10428194.2019.1594220 |
| Alternate Journal | Leuk Lymphoma |
| PubMed ID | 30997845 |
| PubMed Central ID | PMC8162842 |
| Grant List | P30 CA008748 / CA / NCI NIH HHS / United States |
Related Faculty:
Giorgio Inghirami, M.D.